{
"info": {
"nct_id": "NCT06830720",
"official_title": "A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence to Evaluate Real-world Effectiveness, Safety Profile, Patient Compliance and Quality of Life",
"inclusion_criteria": "* Histological diagnosis of HR+/HER2- early breast cancer with curative intent\n* Patients must have an indication for a treatment with ribociclib + NSAI ± LHRH as described in the current SmPC/\"Fachinformation\" of ribociclib (to be included into the cohorts of ribociclib + NSAI ± LHRH and ET mono ± LHRH) or abemaciclib + ET ± LHRH as described in the current SmPC/\"Fachinformation\" of abemaciclib (to be included into the abemaciclib + ET ± LHRH cohort) in the adjuvant setting\n* Before enrollment the treating physician has made the decision in accordance with the patient to treat the patient with either\n\n * ribociclib + NSAI ± LHRH, or\n * ET mono ± LHRH, or\n * abemaciclib + ET ± LHRH and baseline is no longer than 2 weeks (14 days) prior to written informed consent for this study.\n\nBaseline = for ribociclib + NSAI ± LHRH cohort: date of therapy start; for abemaciclib + ET ± LHRH cohort: date of therapy start; for ET mono ± LHRH cohort: 4 weeks after therapy start or 4 weeks after last non-endocrine based therapy, whichever is last.\n\n* ≥18 years of age\n* Written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
"exclusion_criteria": "* Patient is currently under active treatment in any investigational trial or simultaneously participating in another Novartis-sponsored non-interventional study with ribociclib\n* For ribociclib + NSAI ± LHRH cohort: ET pre-treatment is longer than 12 months, according to the current SmPC/\"Fachinformation\" of ribociclib; for abemaciclib + ET ± LHRH cohort: ET pre-treatment is longer than 12 weeks, according to the current SmPC/\"Fachinformation\" of abemaciclib",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Histological diagnosis of HR+/HER2- early breast cancer with curative intent",
"criterions": [
{
"exact_snippets": "Histological diagnosis of HR+/HER2- early breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "histological diagnosis",
"expected_value": "HR+/HER2- early"
}
},
{
"exact_snippets": "curative intent",
"criterion": "treatment intent",
"requirement": {
"requirement_type": "intent",
"expected_value": "curative"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Histological diagnosis of HR+/HER2- early breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "histological diagnosis",
"expected_value": "HR+/HER2- early"
}
},
{
"exact_snippets": "curative intent",
"criterion": "treatment intent",
"requirement": {
"requirement_type": "intent",
"expected_value": "curative"
}
}
]
}
},
{
"identified_line": {
"line": "* Patients must have an indication for a treatment with ribociclib + NSAI ± LHRH as described in the current SmPC/\"Fachinformation\" of ribociclib (to be included into the cohorts of ribociclib + NSAI ± LHRH and ET mono ± LHRH) or abemaciclib + ET ± LHRH as described in the current SmPC/\"Fachinformation\" of abemaciclib (to be included into the abemaciclib + ET ± LHRH cohort) in the adjuvant setting",
"criterions": [
{
"exact_snippets": "indication for a treatment with ribociclib + NSAI ± LHRH as described in the current SmPC/\"Fachinformation\" of ribociclib",
"criterion": "indication for ribociclib + NSAI ± LHRH treatment",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "indication for a treatment with ... abemaciclib + ET ± LHRH as described in the current SmPC/\"Fachinformation\" of abemaciclib",
"criterion": "indication for abemaciclib + ET ± LHRH treatment",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "indication for a treatment with ribociclib + NSAI ± LHRH as described in the current SmPC/\"Fachinformation\" of ribociclib",
"criterion": "indication for ribociclib + NSAI ± LHRH treatment",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "indication for a treatment with ribociclib + NSAI ± LHRH as described in the current SmPC/\"Fachinformation\" of ribociclib",
"criterion": "inclusion into the cohorts of ribociclib + NSAI ± LHRH and ET mono ± LHRH",
"requirement": {
"requirement_type": "eligibility",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "indication for a treatment with ... abemaciclib + ET ± LHRH as described in the current SmPC/\"Fachinformation\" of abemaciclib",
"criterion": "indication for abemaciclib + ET ± LHRH treatment",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "indication for a treatment with ... abemaciclib + ET ± LHRH as described in the current SmPC/\"Fachinformation\" of abemaciclib",
"criterion": "inclusion into the abemaciclib + ET ± LHRH cohort",
"requirement": {
"requirement_type": "eligibility",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Before enrollment the treating physician has made the decision in accordance with the patient to treat the patient with either",
"criterions": [
{
"exact_snippets": "Before enrollment the treating physician has made the decision in accordance with the patient to treat the patient with either",
"criterion": "treatment decision",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Before enrollment the treating physician has made the decision in accordance with the patient to treat the patient with either",
"criterion": "treatment decision",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* ribociclib + NSAI ± LHRH, or",
"criterions": [
{
"exact_snippets": "ribociclib",
"criterion": "ribociclib",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "NSAI",
"criterion": "NSAI",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "LHRH",
"criterion": "LHRH",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "ribociclib",
"criterion": "ribociclib",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "NSAI",
"criterion": "NSAI",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"exact_snippets": "LHRH",
"criterion": "LHRH",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "ribociclib",
"criterion": "ribociclib",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "NSAI",
"criterion": "NSAI",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* ET mono ± LHRH, or",
"criterions": [
{
"exact_snippets": "ET mono",
"criterion": "ET mono",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "LHRH",
"criterion": "LHRH",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "ET mono",
"criterion": "ET mono",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "LHRH",
"criterion": "LHRH",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"exact_snippets": "ET mono",
"criterion": "ET mono",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* abemaciclib + ET ± LHRH and baseline is no longer than 2 weeks (14 days) prior to written informed consent for this study.",
"criterions": [
{
"exact_snippets": "baseline is no longer than 2 weeks (14 days) prior to written informed consent",
"criterion": "baseline timing",
"requirement": {
"requirement_type": "timing",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "baseline is no longer than 2 weeks (14 days) prior to written informed consent",
"criterion": "baseline timing",
"requirement": {
"requirement_type": "timing",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
},
{
"or_criteria": [
{
"exact_snippets": "abemaciclib + ET",
"criterion": "treatment regimen",
"requirement": {
"requirement_type": "combination",
"expected_value": [
"abemaciclib",
"ET"
]
}
},
{
"exact_snippets": "abemaciclib + ET ± LHRH",
"criterion": "treatment regimen",
"requirement": {
"requirement_type": "combination",
"expected_value": [
"abemaciclib",
"ET",
"LHRH"
]
}
}
]
}
]
}
},
{
"identified_line": {
"line": "Baseline = for ribociclib + NSAI ± LHRH cohort: date of therapy start; for abemaciclib + ET ± LHRH cohort: date of therapy start; for ET mono ± LHRH cohort: 4 weeks after therapy start or 4 weeks after last non-endocrine based therapy, whichever is last.",
"criterions": [
{
"exact_snippets": "ribociclib + NSAI ± LHRH cohort: date of therapy start",
"criterion": "ribociclib + NSAI ± LHRH cohort",
"requirement": {
"requirement_type": "date of therapy start",
"expected_value": "N/A"
}
},
{
"exact_snippets": "abemaciclib + ET ± LHRH cohort: date of therapy start",
"criterion": "abemaciclib + ET ± LHRH cohort",
"requirement": {
"requirement_type": "date of therapy start",
"expected_value": "N/A"
}
},
{
"exact_snippets": "ET mono ± LHRH cohort: 4 weeks after therapy start or 4 weeks after last non-endocrine based therapy, whichever is last",
"criterion": "ET mono ± LHRH cohort",
"requirement": {
"requirement_type": "time after therapy start",
"expected_value": {
"operator": "=",
"value": 4,
"unit": "weeks"
}
}
},
{
"exact_snippets": "ET mono ± LHRH cohort: 4 weeks after therapy start or 4 weeks after last non-endocrine based therapy, whichever is last",
"criterion": "ET mono ± LHRH cohort",
"requirement": {
"requirement_type": "time after last non-endocrine based therapy",
"expected_value": {
"operator": "=",
"value": 4,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "ribociclib + NSAI ± LHRH cohort: date of therapy start",
"criterion": "ribociclib + NSAI ± LHRH cohort",
"requirement": {
"requirement_type": "date of therapy start",
"expected_value": "N/A"
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "abemaciclib + ET ± LHRH cohort: date of therapy start",
"criterion": "abemaciclib + ET ± LHRH cohort",
"requirement": {
"requirement_type": "date of therapy start",
"expected_value": "N/A"
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "ET mono ± LHRH cohort: 4 weeks after therapy start or 4 weeks after last non-endocrine based therapy, whichever is last",
"criterion": "ET mono ± LHRH cohort",
"requirement": {
"requirement_type": "time after therapy start",
"expected_value": {
"operator": "=",
"value": 4,
"unit": "weeks"
}
}
},
{
"exact_snippets": "ET mono ± LHRH cohort: 4 weeks after therapy start or 4 weeks after last non-endocrine based therapy, whichever is last",
"criterion": "ET mono ± LHRH cohort",
"requirement": {
"requirement_type": "time after last non-endocrine based therapy",
"expected_value": {
"operator": "=",
"value": 4,
"unit": "weeks"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* ≥18 years of age",
"criterions": [
{
"exact_snippets": "≥18 years of age",
"criterion": "age",
"requirement": {
"requirement_type": "age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "≥18 years of age",
"criterion": "age",
"requirement": {
"requirement_type": "age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Written informed consent",
"criterions": [
{
"exact_snippets": "Written informed consent",
"criterion": "informed consent",
"requirement": {
"requirement_type": "form",
"expected_value": "written"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Written informed consent",
"criterion": "informed consent",
"requirement": {
"requirement_type": "form",
"expected_value": "written"
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
},
{
"identified_line": {
"line": "Must have maximum age of 100 Years",
"criterions": [
{
"exact_snippets": "maximum age of 100 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 100,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "maximum age of 100 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 100,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* For ribociclib + NSAI ± LHRH cohort: ET pre-treatment is longer than 12 months, according to the current SmPC/\"Fachinformation\" of ribociclib; for abemaciclib + ET ± LHRH cohort: ET pre-treatment is longer than 12 weeks, according to the current SmPC/\"Fachinformation\" of abemaciclib",
"criterions": [
{
"exact_snippets": "ribociclib + NSAI ± LHRH cohort: ET pre-treatment is longer than 12 months",
"criterion": "ET pre-treatment duration for ribociclib + NSAI ± LHRH cohort",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 12,
"unit": "months"
}
}
},
{
"exact_snippets": "abemaciclib + ET ± LHRH cohort: ET pre-treatment is longer than 12 weeks",
"criterion": "ET pre-treatment duration for abemaciclib + ET ± LHRH cohort",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 12,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "ribociclib + NSAI ± LHRH cohort: ET pre-treatment is longer than 12 months",
"criterion": "ET pre-treatment duration for ribociclib + NSAI ± LHRH cohort",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 12,
"unit": "months"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "abemaciclib + ET ± LHRH cohort: ET pre-treatment is longer than 12 weeks",
"criterion": "ET pre-treatment duration for abemaciclib + ET ± LHRH cohort",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 12,
"unit": "weeks"
}
}
}
]
}
]
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"identified_line": {
"line": "* Patient is currently under active treatment in any investigational trial or simultaneously participating in another Novartis-sponsored non-interventional study with ribociclib",
"criterions": [
{
"exact_snippets": "Patient is currently under active treatment in any investigational trial",
"criterion": "active treatment in investigational trial",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "simultaneously participating in another Novartis-sponsored non-interventional study with ribociclib",
"criterion": "participation in Novartis-sponsored non-interventional study with ribociclib",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Patient is currently under active treatment in any investigational trial",
"criterion": "active treatment in investigational trial",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "simultaneously participating in another Novartis-sponsored non-interventional study with ribociclib",
"criterion": "participation in Novartis-sponsored non-interventional study with ribociclib",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
}
],
"failed_miscellaneous": []
}